Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity

Journal of Immunology

Volumn 188, Issue 3, 2012, Pages 1451-1459

  Crampton, Steve P ^a   Deane, Jonathan A ^b   Feigenbaum, Lionel ^c   Bolland, Silvia ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD8 ANTIGEN; CYTOKINE; DOUBLE STRANDED RNA; INTERFERON; PROTEIN MDA5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DIABETES MELLITUS; DISEASE ASSOCIATION; GENE; GENE DOSAGE; GLOMERULONEPHRITIS; IFIH1 GENE; IMMUNOCOMPETENT CELL; INFLAMMATION; LETHALITY; LUPUS VULGARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RHABDOVIRUS INFECTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TYPE 1 INTERFERON GENE; VESICULAR STOMATITIS VIRUS; VIRAL CLEARANCE; VIRUS RESISTANCE;

ANIMALS; AUTOIMMUNITY; CELL LINE; DEAD-BOX RNA HELICASES; GENE DOSAGE; INFLAMMATION; INTERFERON TYPE I; MICE; MICE, TRANSGENIC; VIRUS DISEASES; VIRUSES;

EID: 84856574619     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102705     Document Type: Article

References (45)

1. Kumar, H., T. Kawai, and S. Akira. 2011. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30: 16-34.
2. Kawai, T., and S. Akira. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 1143: 1-20.
3. Liu, S. Y., D. J. Sanchez, and G. Cheng. 2011. New developments in the induction and antiviral effectors of type I interferon. Curr. Opin. Immunol. 23: 57-64.
4. Mattei, F., G. Schiavoni, and D. F. Tough. 2010. Regulation of immune cell homeostasis by type I interferons. Cytokine Growth Factor Rev. 21: 227-236.
5. Sozzani, S., D. Bosisio, M. Scarsi, and A. Tincani. 2010. Type I interferons in systemic autoimmunity. Autoimmunity 43: 196-203.
6. Crow, M. K. 2007. Type I interferon in systemic lupus erythematosus. Curr. Top. Microbiol. Immunol. 316: 359-386.
7. Obermoser, G., and V. Pascual. 2010. The interferon-α signature of systemic lupus erythematosus. Lupus 19: 1012-1019.
8. Blanco, P., A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294: 1540-1543. (Pubitemid 33063928)
9. Li, Q. Z., J. Zhou, Y. Lian, B. Zhang, V. K. Branch, F. Carr-Johnson, D. R. Karp, C. Mohan, E. K. Wakeland, and N. J. Olsen. 2010. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin. Exp. Immunol. 159: 281-291.
10. Nacionales, D. C., K. M. Kelly-Scumpia, P. Y. Lee, J. S. Weinstein, R. Lyons, E. Sobel, M. Satoh, and W. H. Reeves. 2007. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56: 3770-3783. (Pubitemid 350100710)
11. -/-mouse models of systemic lupus erythematosus. J. Immunol. 184: 796-806.
12. Santiago-Raber, M. L., R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, D. H. Kono, and A. N. Theofilopoulos. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197: 777-788. (Pubitemid 36350872)
13. Hron, J. D., and S. L. Peng. 2004. Type I IFN protects against murine lupus. J. Immunol. 173: 2134-2142. (Pubitemid 38971652)
14. Schwarting, A., K. Paul, S. Tschirner, J. Menke, T. Hansen, W. Brenner, V. R. Kelley, M. Relle, and P. R. Galle. 2005. Interferon-β: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16: 3264-3272. (Pubitemid 46179332)
15. Christensen, S. R., J. Shupe, K. Nickerson, M. Kashgarian, R. A. Flavell, and M. J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428. (Pubitemid 44354217)
16. Deane, J. A., P. Pisitkun, R. S. Barrett, L. Feigenbaum, T. Town, J. M. Ward, R. A. Flavell, and S. Bolland. 2007. Control of Toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27: 801-810. (Pubitemid 350102256)
17. Pisitkun, P., J. A. Deane, M. J. Difilippantonio, T. Tarasenko, A. B. Satterthwaite, and S. Bolland. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312: 1669-1672. (Pubitemid 43902669)
18. Downes, K., M. Pekalski, K. L. Angus, M. Hardy, S. Nutland, D. J. Smyth, N. M. Walker, C. Wallace, and J. A. Todd. 2010. Reduced expression of IFIH1 is protective for type 1 diabetes. PLoS One 5: e12646.
19. Gateva, V., J. K. Sandling, G. Hom, K. E. Taylor, S. A. Chung, X. Sun, W. Ortmann, R. Kosoy, R. C. Ferreira, G. Nordmark, et al. 2009. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41: 1228-1233.
20. Liu, S., H. Wang, Y. Jin, R. Podolsky, M. V. Reddy, J. Pedersen, B. Bode, J. Reed, D. Steed, S. Anderson, et al. 2009. IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum. Mol. Genet. 18: 358-365.
21. Nejentsev, S., N. Walker, D. Riches, M. Egholm, and J. A. Todd. 2009. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 324: 387-389.
22. Smyth, D. J., J. D. Cooper, R. Bailey, S. Field, O. Burren, L. J. Smink, C. Guja, C. Ionescu-Tirgoviste, B. Widmer, D. B. Dunger, et al. 2006. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 38: 617-619. (Pubitemid 43927300)
23. Fink, J., F. Gu, L. Ling, T. Tolfvenstam, F. Olfat, K. C. Chin, P. Aw, J. George, V. A. Kuznetsov, M. Schreiber, et al. 2007. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl. Trop. Dis. 1: e86.
24. Ubol, S., P. Masrinoul, J. Chaijaruwanich, S. Kalayanarooj, T. Charoensirisuthikul, and J. Kasisith. 2008. Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. J. Infect. Dis. 197: 1459-1467. (Pubitemid 351711266)
25. Walsh, R. J., S. W. Kong, Y. Yao, B. Jallal, P. A. Kiener, J. L. Pinkus, A. H. Beggs, A. A. Amato, and S. A. Greenberg. 2007. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56: 3784-3792. (Pubitemid 350100711)
26. Van Bleek, G. M., and S. G. Nathenson. 1990. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 348: 213-216.
27. Hole, K., A. Clavijo, and L. A. Pineda. 2006. Detection and serotype-specific differentiation of vesicular stomatitis virus using a multiplex, real-time, reverse transcription-polymerase chain reaction assay. J. Vet. Diagn. Invest. 18: 139-146.
28. Trinchieri, G. 2010. Type I interferon: friend or foe? J. Exp. Med. 207: 2053-2063.
29. Seo, Y. J., and B. Hahm. 2010. Type I interferon modulates the battle of host immune system against viruses. Adv. Appl. Microbiol. 73: 83-101.
30. Dumont, F. J., and L. Z. Coker. 1986. Interferon-α/β enhances the expression of Ly-6 antigens on T cells in vivo and in vitro. Eur. J. Immunol. 16: 735-740. (Pubitemid 16075771)
31. Blasius, A. L., E. Giurisato, M. Cella, R. D. Schreiber, A. S. Shaw, and M. Colonna. 2006. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 177: 3260-3265. (Pubitemid 44277845)
32. Müller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921. (Pubitemid 24245635)
33. Novick, D., B. Cohen, and M. Rubinstein. 1994. The human interferon α/βreceptor: characterization and molecular cloning. Cell 77: 391-400. (Pubitemid 24145200)
34. Hangartner, L., R. M. Zinkernagel, and H. Hengartner. 2006. Antiviral antibody responses: the two extremes of a wide spectrum. Nat. Rev. Immunol. 6: 231-243. (Pubitemid 43290992)
35. Bolland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13: 277-285.
36. Pavlovic, J., T. Zürcher, O. Haller, and P. Staeheli. 1990. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J. Virol. 64: 3370-3375. (Pubitemid 20219541)
37. Harty, R. N., P. M. Pitha, and A. Okumura. 2009. Antiviral activity of innate immune protein ISG15. J. Innate Immun. 1: 397-404.
38. Means, R. T., Jr., and S. B. Krantz. 1992. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639-1647.
39. Weiss, G., and L. T. Goodnough. 2005. Anemia of chronic disease. N. Engl. J. Med. 352: 1011-1023.
40. Alanoglu, G., S. Kilbas, C. Arslan, A. Senol, and S. Kutluhan. 2007. Autoimmune hemolytic anemia during interferon-β-I b treatment for multiple sclerosis. Mult. Scler. 13: 683-685. (Pubitemid 46939540)
41. Bolland, S., Y. S. Yim, K. Tus, E. K. Wakeland, and J. V. Ravetch. 2002. Genetic modifiers of systemic lupus erythematosus in FcγRIIB-/- mice. J. Exp. Med. 195: 1167-1174. (Pubitemid 34517142)
42. Bekeredjian-Ding, I. B., M. Wagner, V. Hornung, T. Giese, M. Schnurr, S. Endres, and G. Hartmann. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174: 4043-4050. (Pubitemid 40395980)
43. Thibault, D. L., A. D. Chu, K. L. Graham, I. Balboni, L. Y. Lee, C. Kohlmoos, A. Landrigan, J. P. Higgins, R. Tibshirani, and P. J. Utz. 2008. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J. Clin. Invest. 118: 1417-1426. (Pubitemid 351500435)
44. Le Bon, A., G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli, and D. F. Tough. 2001. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470. (Pubitemid 32441598)
45. Marshak-Rothstein, A. 2006. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6: 823-835. (Pubitemid 44631651)